Karen Flynn
2020
In 2020, Karen Flynn earned a total compensation of $2.7M as President, Biologics & Chief Commercial Officer at Catalent.
Compensation breakdown
| Bonus | $200,000 |
|---|---|
| Non-Equity Incentive Plan | $190,789 |
| Salary | $251,491 |
| Stock Awards | $2,000,010 |
| Other | $23,091 |
| Total | $2,665,381 |
Flynn received $2M in stock awards, accounting for 75% of the total pay in 2020.
Flynn also received $200K in bonus, $190.8K in non-equity incentive plan, $251.5K in salary and $23.1K in other compensation.
Rankings
In 2020, Karen Flynn's compensation ranked 4,308th out of 13,090 executives tracked by ExecPay. In other words, Flynn earned more than 67.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,308 out of 13,090 | 67th |
Division Manufacturing | 1,741 out of 5,620 | 69th |
Major group Chemicals And Allied Products | 679 out of 2,253 | 70th |
Industry group Drugs | 580 out of 1,953 | 70th |
Industry Pharmaceutical Preparations | 441 out of 1,458 | 70th |
Source: SEC filing on September 17, 2021.
Flynn's colleagues
We found four more compensation records of executives who worked with Karen Flynn at Catalent in 2020.